| Trial | Sponsor | Phase | Status | Primary completion |
|---|
| A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe HypertriglyceridemiaNCT05610280 | IONS | Phase 3 | Completed | 2024-08-08Actual |
| Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial CarcinomaNCT05611931 | KPTI | Phase 3 | Active not recruiting | 2026-05-22Actual |
| A Randomized Study of XEN1101 Versus Placebo in Focal-Onset SeizuresNCT05614063 | XENE | Phase 3 | Completed | 2026-01-12Actual |
| Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa InfectionNCT05616221 | ARMP | Phase 2 | Completed | 2024-07-17Actual |
| A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19NCT05616728 | ENTA | Phase 2 | Completed | 2023-02-08Actual |
| A Prospective Clinical Trial to Evaluate the Efficacy and Safety of Neurotropic B-Vitamins in Clinically Diagnosed Peripheral Sensory Polyneuropathy of Different Etiologies.NCT05619328 | Procter and Gamble | Phase 3 | Completed | 2023-11-02Actual |
| A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)NCT05619692 | SUPN | Phase 2 | Completed | 2024-06-05Actual |
| Extension Study Evaluating The Safety And Tolerability of AMX0035NCT05619783 | AMLX | Phase 3 | Completed | 2024-10-16Actual |
| Imaging Evaluation of PLN-74809 in Participants With IPF (PLN-74809)NCT05621252 | PLRX | Phase 2 | Completed | 2023-12-27Actual |
| Efficacy, Safety, and Tolerability of COMP360 in Participants With TRDNCT05624268 | COMPASS Pathways | Phase 3 | Completed | 2025-05-28Actual |
| A Study to Determine the Safety and Immunogenicity of Bivalent GI.1 and GII.4 Vaccines in Healthy VolunteersNCT05626803 | Vaxart | Phase 2 | Completed | 2023-10-16Actual |
| Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of ApitegromabNCT05626855 | Scholar Rock, Inc. | Phase 3 | Active not recruiting | 2026-11-01Estimated |
| A Multi-Centre, Randomised, Controlled, Masked Phase 2 Study of the Safety and Efficacy of KIO-101 Ophthalmic Solution, Versus Vehicle Control in the Treatment of Dry Eye Disease in Patients With Autoimmune DiseaseNCT05629364 | KPRX | Phase 2 | Terminated | 2024-01-09Actual |
| Trial to Evaluate the Efficacy and Safety of TP-03, LIBRA StudyNCT05629390 | LianBio LLC | Phase 3 | Completed | 2023-09-15Actual |
| SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19NCT05629962 | AVIR | Phase 3 | Completed | 2024-04-25Actual |
| A Study of Botensilimab in Participants With Metastatic Pancreatic CancerNCT05630183 | AGEN | Phase 2 | Completed | 2026-01-05Actual |
| Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic ArthritisNCT05640245 | MoonLake Immunotherapeutics AG | Phase 2 | Completed | 2023-09-05Actual |
| A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's DiseaseNCT05642442 | Jazz Pharmaceuticals | Phase 2 | Completed | 2024-10-23Actual |
| Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 YearsNCT05643534 | Ardelyx | Phase 3 | Completed | 2026-08-20Actual |
| An Open-Label Study Evaluating Brexanolone in Adults With TinnitusNCT05645432 | SUPN | Phase 2 | Completed | 2023-11-21Actual |
| Safety and Efficacy of FSD201 for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD)NCT05652907 | Quantum Biopharma | Phase 2 | Terminated | 2023-05-24Actual |
| A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's DiseaseNCT05655520 | SUPN | Phase 3 | Terminated | 2025-01-20Actual |
| Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)NCT05658510 | BioXcel Therapeutics Inc | Phase 3 | Completed | 2025-08-15Actual |
| Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED LampNCT05662202 | BFRI | Phase 3 | Completed | 2025-09-03Actual |
| A Phase 3 Study of Obexelimab in Patients With IgG4-Related DiseaseNCT05662241 | Zenas BioPharma (USA), LLC | Phase 3 | Active not recruiting | 2025-11-13Actual |
| NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell LymphomaNCT05664217 | NKTR | Phase 2, Phase 3 | Terminated | 2024-05-22Actual |
| Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III)NCT05665088 | BioXcel Therapeutics Inc | Phase 3 | Terminated | 2023-09-11Actual |
| A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic SeizuresNCT05667142 | XENE | Phase 3 | Recruiting | 2027-04Estimated |
| An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)NCT05667493 | IONS | Phase 3 | Enrolling by invitation | 2029-08Estimated |
| Study to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults With Asthma and ABPANCT05667662 | PULM | Phase 2 | Terminated | 2024-02-27Actual |
Trial details
- Registry ID
- NCT05610280
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05611931
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05614063
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05616221
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05616728
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05619328
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05619692
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05619783
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05621252
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05624268
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05626803
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05626855
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05629364
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05629390
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05629962
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05630183
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05640245
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05642442
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05643534
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05645432
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05652907
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05655520
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05658510
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05662202
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05662241
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05664217
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT05665088
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05667142
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05667493
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05667662
- Phase
- Phase 2
Primary completion marks the end of data collection for the main study measures, not a results publication date.